Oleclumab

Summary

Oleclumab (CHEMBL3990016) is a phase-3 clinical-stage antibody targeting NT5E; indicated across 11 conditions including non-small cell lung carcinoma and exocrine pancreatic carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (NT5E)
• Indications: 11 conditions
• Clinical trials: 28

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990016
Name	Oleclumab
Type	Antibody
Max phase	3

Also known as: MEDI-9447, MEDI9447, Oleclumab, OLECLUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NT5E	Ecto-5’-Nucleotidase	Binding	11.38	0%	P21589

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): NT5E.

Top Reactome pathways

14 total, by targets touching each:

Pathway	Targets	Genes
Metabolism	1	NT5E
Metabolism of nucleotides	1	NT5E
Disease	1	NT5E
Nicotinate metabolism	1	NT5E
Metabolism of water-soluble vitamins and cofactors	1	NT5E
Metabolism of vitamins and cofactors	1	NT5E
Infectious disease	1	NT5E
Pyrimidine catabolism	1	NT5E
Purine catabolism	1	NT5E
Nucleotide catabolism	1	NT5E
Leishmania infection	1	NT5E
Purinergic signaling in leishmaniasis infection	1	NT5E
Cell recruitment (pro-inflammatory response)	1	NT5E
Parasitic Infection Pathways	1	NT5E

Dominant GO biological processes

GO term	Targets
AMP catabolic process	1
DNA metabolic process	1
leukocyte cell-cell adhesion	1
response to ATP	1
ADP catabolic process	1
ATP metabolic process	1
adenosine biosynthetic process	1
negative regulation of inflammatory response	1
calcium ion homeostasis	1
inhibition of non-skeletal tissue mineralization	1
nucleotide catabolic process	1

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
colorectal carcinoma	2	MONDO:0024331	EFO:1001951
pancreatic ductal adenocarcinoma	2	MONDO:0005184	MONDO:0005184
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
neoplasm	1	MONDO:0005070	EFO:0000616
breast neoplasm	1	MONDO:0021100	EFO:0003869

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 28.

Phase distribution

Phase	Trials
PHASE2	15
PHASE1	7
PHASE1/PHASE2	5
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05221840	PHASE3	ACTIVE_NOT_RECRUITING	A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT03334617	PHASE2	ACTIVE_NOT_RECRUITING	Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
NCT03381274	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
NCT03616886	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC
NCT03742102	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03833440	PHASE2	ACTIVE_NOT_RECRUITING	Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
NCT03875573	PHASE2	ACTIVE_NOT_RECRUITING	Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
NCT04068610	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
NCT04668300	PHASE2	ACTIVE_NOT_RECRUITING	Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
NCT04940286	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT05061550	PHASE2	RECRUITING	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT06060405	PHASE2	RECRUITING	Durvalumab and Oleclumab in Resectable PDAC
NCT06606847	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
NCT07146230	PHASE2	NOT_YET_RECRUITING	The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
NCT03611556	PHASE1/PHASE2	COMPLETED	MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03794544	PHASE2	COMPLETED	Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
NCT03822351	PHASE2	COMPLETED	Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
NCT04089553	PHASE2	COMPLETED	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
NCT04145193	PHASE2	WITHDRAWN	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
NCT04262375	PHASE2	WITHDRAWN	A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
NCT04262388	PHASE2	WITHDRAWN	A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
NCT03819465	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
NCT02503774	PHASE1	COMPLETED	MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
NCT02740985	PHASE1	COMPLETED	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
NCT03736473	PHASE1	COMPLETED	A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
NCT03773666	PHASE1	COMPLETED	A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
NCT03801902	PHASE1	COMPLETED	Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
NCT04261075	PHASE1	COMPLETED	IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

7 molecules share ≥1 primary target. Top 7 by shared-target count:

Molecule	Source	Status	Shared targets
FLUDARABINE	ChEMBL + PubChem	Phase 3 (approved)	NT5E
QUERCETIN	ChEMBL + PubChem	Phase 3 (approved)	NT5E
ELLAGIC ACID	ChEMBL	Phase 2	NT5E
FTIVAZIDE	ChEMBL	Phase 2	NT5E
QUEMLICLUSTAT	ChEMBL	Phase 2	NT5E
adenosine	PubChem	Approved	NT5E
Tiamulin	PubChem	Approved	NT5E